Recent research suggests that there may be different types of preeclampsia (such as early- versus late-onset, with or without severe features, HELLP syndrome, and postpartum-onset). These type of preeclampsia may also vary based on specific individual risk factors. One risk factor that researchers have identified is a woman's body mass index (aka BMI), a number calculated from a patient's height and weight.
In this study, researchers asked: are there biomarkers (molecules measured in the blood) in early pregnancy that can predict preterm preeclampsia later in pregnancy? And if so, are those biomarkers different in women in different BMI groups (healthy, overweight, obese)? Researchers found distinct levels of certain metabolites (small products of metabolism) in blood drawn in early pregnancy that were linked to developing preterm preeclampsia later in that pregnancy. Interestingly, one metabolite was a form of vitamin D (25-hydroxyvitamin D3). Others were small fatty acids and individual amino acids (the building blocks of protein). When comparing metabolites and their ratios to one another among women in different BMI groups, researchers also found among women who went on to develop preterm preeclampsia, that metabolites in early pregnancy were different depending on BMI groups, particularly for women with overweight and obesity.
Take home message: As preeclampsia research continues to move forward at an accelerated pace, research is revealing possible differences not only in “types” of preeclampsia, but also differences in maternal risk profiles. This study suggests that women of different BMI classes might have distinct risk profiles for preeclampsia. More work is needed to refine risk factors for individuals, with the ultimate goal of having an early-pregnancy screening test to predict preeclampsia.
Link: https://www.ajog.org/article/S0002-9378(22)02290-6/pdf
Citation: Tuytten R, Syngelaki A, Thomas G, Panigassi A, Brown LW, Ortea P, Nicolaides KH. First Trimester Preterm Preeclampsia Prediction with Metabolite Biomarkers: Differential Prediction According to Maternal Body Mass Index. Am J Obstet Gynecol. 2022 Dec 17:S0002-9378(22)02290-6. doi: 10.1016/j.ajog.2022.12.012. Epub ahead of print. PMID: 36539025.
Each quarter, our team of researchers reviews the most current studies related to hypertensive disorders of pregnancy and selects those studies they feel will be of greatest interest to our community to summarize.
Special thanks to our volunteer research team, who under the leadership of Dr. Elizabeth Sutton, make Research Roundup possible: Alisse Hauspurg, MD Felicia LeMoine, and MD Jenny Sones, PhD, DVM.
Preeclampsia is a major cause of maternal and fetal morbidity and mortality. Prompt and accurate diagnosis is necessary to prevent adverse outcomes. A study was completed to determine the accura...
Predicting preeclampsia has proven to be a challenge. Researchers have documented many differences in early pregnancy between those who eventually develop preeclampsia and those who do not. These incl...
The U.S. Preventive Services Task Force (USPSTF) and American College of Obstetricians and Gynecologists (ACOG) guidelines changed in 2021 to help prevent preeclampsia. Low-dose aspirin has been shown...
Hypertensive disorders of pregnancy (HDP), including preeclampsia, affect 1 in 6 pregnancies. HDP is a general term for a range of mild to severe outcomes. Until now there has not been a reliabl...
Although there is no definitive treatment for preeclampsia, early screening and detection can allow patients to ensure proper management throughout the remainder of the pregnancy. Currently, preeclam...